|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Stempoint Capital LP
✚
|
|
|---|---|
| CRD # | 324248 |
| SEC # | 801-127041 |
| CIK # | 0001952142 |
| AUM | $625.0 M (2025-04-28) |
| Employees | 6 (50% Investors, 0% Brokers) |
| Phone | 212-540-4099 |
| Address | 520 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Health Sciences Acquisitions Corp | 22.4 | ||
| Syndax Pharmaceuticals Inc | 22.2 | ||
| Scholar Rock Holding Corp | 18.7 | ||
| Roivant Sciences Ltd | 17.1 | ||
| Centessa Pharmaceuticals PLC | 16.6 | ||
| Synta Pharmaceuticals Corp | 15.9 | ||
| Merus NV | 14.0 | ||
| Arcellx Inc | 13.3 | ||
| Cidara Therapeutics Inc | 13.0 | ||
| Rhythm Pharmaceuticals Inc | 11.2 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| HF | Stempoint Capital Opportunity Master Fund LP | [2025-03-28] | 53.1 | 48.9 |
| HF | Stempoint Capital Master Fund LP | [2023-02-02] | 60.4 | 349.7 |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 436.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 188.2 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 625.0 |
| By Discretionary | ||
| Discretionary | 8 | 625.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 625.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 436.8 | |
| United States Persons | 188.2 | |
| Total | 8 | 625.0 |
| Form D Directors | # Filings | # Firms | 2011 - 2025 |
|---|---|---|---|
| Robert Duggan | 29 | ||
| Miles Perryman | 7 | ||
| Sean Tan | 9 | ||
| Stempoint Capital LP | 4 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001952142] | |
| SC 13G | [0001952142] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Stempoint Capital LP | Surrozen Inc/DE | [2024-11-01] |
| Stempoint Capital LP | Vistagen Therapeutics Inc | [2024-02-12] |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Boone Capital Management LLC
✚
|
GA | 0.6 |
|
Harber Capital LLC
✚
|
NC | 0.6 |
|
Topline Capital Management LLC
✚
|
0.6 | |
|
Barnegat Fund Management Inc
✚
|
NJ | 0.6 |
|
Arrington Capital Investment Management LLC
✚
|
FL | 0.6 |
|
Fivespan Partners LP
✚
|
CA | 0.6 |
|
Artia Global Partners LP
✚
|
FL | 0.6 |
|
Rhino Investment Partners Inc
✚
|
PA | 0.6 |
|
Nokomis Capital LLC
✚
|
TX | 0.6 |
|
ProSight Management LP
✚
|
TX | 0.6 |